The comparative efficacy and safety of carotid stenting vs. endarterectomy in asymptomatic carotid stenosis patients remains controversial and, what is worse, consensus seems unlikely in the near future. Given the lack of definite evidence, several meta-analyzis and systematic reviews have been produced in an attempt to shed some light on this matter. This study included all…
It Is a Fact: Cerebral Protection in TAVR Has Proved to Reduce Stroke and Death
Cerebral ischemic events after transcatheter aortic valve replacement (TAVR) have been identified as independent predictors of morbidity and mortality. New-generation devices have managed to partially reduce the rate of cerebral events, but it still is around 5.5% at 30 days for patients undergoing TAVR through transfemoral access. First data on cerebral protection devices had only shown…
CLOSE Trial: Patients with PFO with high flow or associated with interatrial septal aneurysm receiving closure device experience lower rates of recurrent stroke
Several cases have shown an association between patent foramen ovale and cryptogenic shock, particularly in patients under 55 and in those with atrial septal aneurysm or a significant right-to-left shunt. Using PFO closure for stroke prevention has been controversial and, so far, no randomized studies have shown the superiority of this strategy compared to anti-thrombotic…
REDUCE Trial: Patients with PFO and cryptogenic stroke at lower risk of recurrent stoke when treated with APT and closure device
Courtesy of Dr. José Álvarez. This is a multicenter randomized study on patients with patent foramen ovale (PFO) and a first episode of cryptogenic stroke. It only included patients with moderate to large shunt based on the number of bubbles observed in the left atrium within the first three beats after being noticed in the…
Long-term results of the RESPECT study favor closure with the Amplatzer device
Courtesy of Dr. José Álvarez. The RESPECT trial is a multicenter randomized trial with blinded adjudication of end-point events. It randomly assigned patients from 18 to 60 years of age who had a patent foramen ovale (PFO) and a history of cryptogenic ischemic stroke to undergo closure of the PFO with the Amplatzer device plus medical…
SOLACI CACI 2017 | When is the optimal timing for PCI: before or during TAVI
Read articles on the main presentations of the third day of SOLACI-CACI 2017 Congress. See the presentation by Dr. Conrad Simpfendorfer, entitled “When is the optimal timing for PCI: before or during TAVI”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.
SOLACI CACI 2017 | TAVI intermediate risk: Reality or passion?
Read articles on the main presentations of the third day of SOLACI-CACI 2017 Congress. See the presentation by Dr. Flavio Ribichini, entitled “TAVI intermediate risk: Reality or passion?”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.
SOLACI CACI 2017 | TAVI: Clinical Evidence of long term durability of prosthetic valves
Read articles on the main presentations of the third day of SOLACI-CACI 2017 Congress. See the presentation by Dra. Carla Agatiello, entitled “TAVI: Clinical Evidence of long term durability of prosthetic valves”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.
SOLACI CACI 2017 | Clinical evidence of TAVR in intermediate risk patients: Lessons from clinical trials
Read articles on the main presentations of the second day of SOLACI-CACI 2017 Congress. See the presentation by Dr. Andreas Baumbach, entitled “Clinical evidence of TAVR in intermediate risk patients: Lessons from clinical trials”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.
SOLACI CACI | TAVI: Evidencia para pacientes de riesgo intermedio
Read articles on the main presentations of the second day of SOLACI-CACI 2017 Congress. See the presentation by Dr. Oscar Méndiz, entitled “TAVI: Evidencia para pacientes de riesgo intermedio”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.